Influence of estradiol deficiency on the mineralocorticoid receptor response in postmenopausal women: a cross-sectional study
Authors:
- Alejandra Martínez-GarcíaAMAlejandra Martínez-García
- Jorge A. PérezJPJorge A. Pérez
- Alejandra Tapia-CastilloATAlejandra Tapia-Castillo
- María P. HernándezMHMaría P. Hernández
- Marlin SolórzanoMSMarlin Solórzano
- Pablo CarriónPCPablo Carrión
- Carlos E. FardellaCFCarlos E. Fardella
- Cristian A. CarvajalCCCristian A. Carvajal
- 10 February 2025
- journal article
- Published by Taylor & Francis in Climacteric
- Vol. 28 (2) , 162-168
Abstract
Premenopausal women (PreM) have a cardioprotective advantage over postmenopausal women (PostM) due to estrogen. The interaction of estrogen with the mineralocorticoid receptor (MR) pathway remains unexplored. This study aimed to identify changes in aldosterone, renin and sexual steroid levels and MR surrogate biomarkers in PostM that may explain changes in blood pressure and renal damage. A cross-sectional study was carried out with 47 normotensive and hypertensive Chilean women distributed between PreM and PostM. Clinical, anthropometric and biochemical parameters, including aldosterone, plasma renin activity (PRA) and surrogate markers of MR activity, were assessed. PostM had greater systolic blood pressure (SBP) (p < 0.001) than PreM. A negative correlation was observed between estradiol and fractional excretion of potassium (FEK) (ρ = -0.29; p = 0.023), adjusted for age and SBP. Compared with hypertensive PreM, hypertensive PostM (PostM-HT) showed reduced PRA (p = 0.045) and greater FEK (p = 0.04). Normotensive PostM (Post-NT) exhibited greater SBP (p = 0.03), neutrophil gelatinase-associated lipocalin (NGAL) levels (p = 0.04) and FEK (p = 0.03) than normotensive PreM. Our results suggest enhanced MR sensitivity not only in PostM-HT, as evidenced by lower PRA and elevated FEK, but also in PostM-NT, who exhibited greater FEK and NGAL levels, surrogate markers of MR activation. These results support a novel role of MR activation and cardiovascular risk in PostM women.Keywords
Funding Information
- ANID-CONICYT FONDECYT (1212006])
- Fondecyt Postdoctoral (3200646])
- SOCHED (2022-06])
This publication has 49 references indexed in Scilit:
- The Renin-Angiotensin-Aldosterone System in Postmenopausal Women: The Promise of Hormone TherapyMayo Clinic Proceedings, 2021
- Sex differences in cardiovascular actions of the renin–angiotensin systemClinical Autonomic Research, 2020
- Sex Differences in Blood Pressure Trajectories Over the Life CourseJAMA Cardiology, 2020
- Role of estrogen receptors in modulating aldosterone biosynthesis and blood pressureSteroids, 2019
- Sex-specific differences in hypertension and associated cardiovascular diseaseNature Reviews Nephrology, 2018
- Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologiesBiomedicine & Pharmacotherapy, 2017
- Genomic and rapid effects of aldosterone: what we know and do not know thus farHeart Failure Reviews, 2016
- The Role of Aldosteronism in Causing Obesity-Related Cardiovascular RiskCardiology Clinics, 2010
- Plasma Osteopontin Levels Are Higher in Patients With Primary Aldosteronism Than in Patients With Essential HypertensionAmerican Journal of Hypertension, 2006
- Effects of estrogens and progestogens on the renin-aldosterone system and blood pressureSteroids, 1996